The stock has a 36-month beta value of 0.84. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 6 as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for BPMC is 62.21M, and at present, short sellers hold a 9.11% of that float. On June 02, 2025, the average trading volume of BPMC was 991.09K shares.
BPMC) stock’s latest price update
Blueprint Medicines Corp (NASDAQ: BPMC)’s stock price has surge by 26.00relation to previous closing price of 101.35. Nevertheless, the company has seen a 25.81% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-02 that SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY).
BPMC’s Market Performance
Blueprint Medicines Corp (BPMC) has seen a 25.81% rise in stock performance for the week, with a 28.67% gain in the past month and a 42.29% surge in the past quarter. The volatility ratio for the week is 5.47%, and the volatility levels for the past 30 days are at 2.97% for BPMC. The simple moving average for the past 20 days is 25.80% for BPMC’s stock, with a 36.38% simple moving average for the past 200 days.
Analysts’ Opinion of BPMC
Morgan Stanley, on the other hand, stated in their research note that they expect to see BPMC reach a price target of $100. The rating they have provided for BPMC stocks is “Equal-Weight” according to the report published on March 20th, 2025.
BPMC Trading at 37.59% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 4.76% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Albers Jeffrey W., who sale 5,000 shares at the price of $101.14 back on May 27 ’25. After this action, Albers Jeffrey W. now owns 146,630 shares of Blueprint Medicines Corp, valued at $505,692 using the latest closing price.
Albers Jeffrey W., the Director of Blueprint Medicines Corp, proposed sale 5,000 shares at $101.14 during a trade that took place back on May 27 ’25, which means that Albers Jeffrey W. is holding shares at $505,686 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -0.31 for the present operating margin
- 0.96 for the gross margin
The net margin for Blueprint Medicines Corp stands at -0.28. The total capital return value is set at -0.18. Equity return is now at value -47.71, with -13.94 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -1.19. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -3.82.
Currently, EBITDA for the company is 19.23 million with net debt to EBITDA at -0.0. When we switch over and look at the enterprise to sales, we see a ratio of 14.67. The receivables turnover for the company is 7.04for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.80.
Conclusion
To sum up, Blueprint Medicines Corp (BPMC) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
